Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 10, 2006, Pages 904-908

  Burkhardt, Olaf ^a,b   Derendorf, Hartmut ^a   Jäger, Doris ^c   Kumar, Vipul ^a   Madabushi, Rajanikanth ^a   Röhl, Klaus ^c   Barth, Jürgen ^c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c BG KLINIKEN BERGMANNSTROST   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CASE REPORT; CLINICAL TRIAL; DECUBITUS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG SALIVA LEVEL; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HUMAN; IN VIVO STUDY; INTERSTITIAL FLUID; MALE; MICRODIALYSIS; OPEN STUDY; PARALLEL DESIGN; SPINAL CORD INJURY; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; HUMANS; MALE; MICRODIALYSIS; MIDDLE AGED; PRESSURE ULCER; QUINOLINES; SPINAL CORD INJURIES; TISSUE DISTRIBUTION;

EID: 33749379014     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540600664076     Document Type: Article

References (24)

1. Bell, GB. (1999) Spinal cord injury, pressure ulcers, and support surfaces Ostomy Wound Manage, 45, pp. 48-53.
2. Caliri, MH. (2005) Spinal cord injury and pressure ulcers Nurs Clin North Am, 40, pp. 337-47.
3. Gefen, A and Gefen, N and Linder-Ganz, E and Margulies, SS. (2005) In vivo muscle stiffening under bone compression promotes deep pressure sores J Biomech Eng, 127, pp. 512-24.
4. Liu, P and Derendorf, H. (2003) Antimicrobial tissue concentrations Infect Dis Clin North Am, 17, pp. 599-613.
5. Müller, M and de la Pena, A and Derendorf, H. (2004) Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue Antimicrob Agents Chemother, 48, pp. 1441-53.
6. Raghavan, M and Linden, PK. (2004) Newer treatment options for skin and soft tissue infections Drugs, 64, pp. 1621-42.
7. Keating, GM and Scott, LJ. (2004) Moxifloxacin: A review of its use in the management of bacterial infections Drugs, 64, pp. 2347-77.
8. Dalhoff, A and Petersen, U and Endermann, E. (1996) In vitro activity of Bay 12-8039, a new 8-methoxyquinolone Chemotherapy, 42, pp. 410-25.
9. Woodcock, JM and Andrews, JM and Boswell, FJ and Brenwald, NP and Wise, R. (1997) In vitro activity of Bay 12-8039, a new fluoroquinolone Antimicrob Agents Chemother, 41, pp. 101-6.
10. Parish, LC and Routh, HB and Miskin, B and Fidelholtz, J and Werschler, P and Heyd, A and (2000) Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections Int J Clin Pract, 54, pp. 497-503.
11. Giordano, P and Song, J and Pertel, P and Herrington, J and Kowalsky, S. (2005) Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection Int J Antimicrob Agents, 26, pp. 357-65.
12. Müller, M and Stass, H and Brunner, M and Möller, JG and Lackner, E and Eichler, HG. (1999) Penetration of moxifloxacin into peripheral compartments in humans Antimicrob Agents Chemother, 43, pp. 2345-9.
13. Joukhadar, C and Stass, H and Müller-Zellenberg, U and Lackner, E and Kovar, F and Minar, E and Müller, M. (2003) Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans Antimicrob Agents Chemother, 47, pp. 3099-103.
14. Brunner, M and Pernerstorfer, T and Mayer, BX and Eichler, HG and Müller, M. (2000) Surgery and intensive care procedures affect the target site distribution of piperacillin Crit Care Med, 28, pp. 1754-9.
15. Joukhadar, C and Frossard, M and Mayer, BX and Brunner, M and Klein, N and Siostrzonek, P and (2001) Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock Crit Care Med, 29, pp. 385-91.
16. Clough, GF and Boutsiouki, P and Church, MK and Michel, CC. (2002) Effects of blood flow on the in vivo recovery of a small diffusible molecule by microdialysis in human skin J Pharmacol Exp Ther, 302, pp. 681-6.
17. Joukhadar, C and Klein, N and Frossard, M and Minar, E and Stass, H and Lackner, E and (2001) Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease Clin Pharmacol Ther, 70, pp. 532-9.
18. Stass, H and Dalhoff, A. (1997) Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing J Chromatogr B Biomed Sci Appl, 702, pp. 163-74.
19. Joukhadar, C and Klein, N and Frossard, M and Minar, E and Stass, H and Lackner, E and (2001) Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease Clin Pharmacol Ther, 70, pp. 532-9.
20. Schentag, JJ and Meagher, AK and Forrest, A. (2003) Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates. Part I: In vitro and animal models Ann Pharmacother, 37, pp. 1287-98.
21. Schentag, JJ and Meagher, AK and Forrest, A. (2003) Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates. Part 2: Human trials Ann Pharmacother, 37, pp. 1478-88.
22. Burkhardt, O and Borner, K and Stass, H and Beyer, G and Allewelt, M and Nord, CE and Lode, H. (2002) Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces Scand J Infect Dis, 34, pp. 898-903.
23. Burkhardt, O and Stass, H and Thuss, U and Borner, K and Welte, T. (2005) Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers Clin Pharmacokinet, 44, pp. 969-76.
24. Dalhoff, A and Schmitz, FJ. (2003) In vitro antibacterial activity and pharmacodynamics of new fluoroquinolones Eur J Clin Microbiol Infect Dis, 22, pp. 203-21.